Amgen selects Genome Valley for new R&D site; operational by 2027
Hyderabad — US biopharmaceutical major Amgen has announced plans to set up a new science and innovation centre in Genome Valley, Hyderabad, joining the company’s global research and development network that comprises seven research laboratories worldwide. The company said the facility is expected to be operational in 2027 and will complement its existing global capability centre in the city.
According to the company, the Hyderabad centre will focus on a mix of laboratory science and advanced digital capabilities, aiming to integrate experimental research with data‑driven tools to accelerate discovery and development of medicines. Areas of emphasis named by Amgen include discovery chemistry, drug metabolism and pharmacokinetics, precision medicine, data science and digital technologies.
- Location: Genome Valley, Hyderabad
- Operational timeline: 2027
- Core focus: experimental science + advanced data/technology tools
- Existing presence: Amgen already operates a global capability centre in Hyderabad
“Hyderabad brings together scientific talent, technology and industry at scale and has built one of the world’s strongest life sciences ecosystems, with deep capabilities in pharmaceuticals and vaccines,” Telangana IT & Industries Minister D Sridhar Babu said.
Amgen senior executives framed the new site as a strategic complement to its United States‑based R&D operations. Jay Bradner, executive vice‑president of research and development, artificial intelligence and data, said the Genome Valley centre would help the company connect science, data and technology across its global research system and translate insights into new medicines, according to the company statement. Som Chattopadhyay, senior vice‑president of global business solutions and national executive, said the move highlights India’s growing role in Amgen’s R&D network.
Implications for Hyderabad’s life‑sciences ecosystem
The announcement builds on Hyderabad’s established strengths in pharmaceuticals, vaccines and contract research organisations. By locating a centre that explicitly links wet‑lab discovery with data science and digital technologies, Amgen is signalling confidence in local scientific talent and the supporting infrastructure of Genome Valley — the cluster that hosts multinational and Indian life‑sciences firms, research parks and training institutions.
Telangana’s policymakers have been actively positioning Hyderabad as a global destination for high‑value research and innovation. The IT & Industries Ministry framed Amgen’s decision as part of an ambition to move the city from manufacturing and clinical production towards discovery and early‑stage innovation, leveraging cross‑sector strengths in biotech and information technology.
| Item | Detail |
|---|---|
| Company | Amgen |
| Location | Genome Valley, Hyderabad |
| Operational target | 2027 |
| Focus areas | Discovery chemistry; DMPK; precision medicine; data science; digital technologies |
For Hyderabad, the new centre may deepen linkages between academic institutions, start‑ups and established firms active in drug discovery, bioinformatics and computational biology. The integration of experimental science with advanced data tools — an explicit element of Amgen’s plan — aligns with broader trends in pharmaceutical R&D where machine learning, high‑throughput experiments and systems pharmacology are rapidly becoming core capabilities.
Industry observers and local officials have been emphasising the need to move beyond manufacturing and clinical development to capture higher‑value phases of the innovation chain. If the Amgen centre realises its stated objectives, it could catalyse collaborations, talent development and service‑provider growth in Hyderabad, while further cementing Genome Valley’s reputation as a major research cluster.
The company statement noted that the Hyderabad site will work closely with Amgen research sites globally, and will complement the firm’s existing technology and innovation operations in the city, allowing closer links between wet‑laboratory research and digital innovation. Naveen Gullapalli, managing director of Amgen India, was mentioned in the release as part of the company’s leadership referencing the move.
As the project moves from announcement to planning and construction, details such as investment size, local hiring plans, specific academic partnerships and the precise campus footprint were not disclosed in the statement. Stakeholders in Hyderabad’s life‑sciences ecosystem will be watching for those operational specifics, which will determine how quickly the centre can contribute to local research capacity and industry growth.
